Fig. 1

Clinical course of a patient with hereditary angioedema and acute myeloid leukemia. At the age of 39 years, the patient had AML and received BMT from a bone marrow bank. Consequently, he fully recovered from AML and remained in remission. Before he underwent BMT, he experienced acute HAE attacks approximately every 3 months from his 20 s. After BMT, his plasma C1-INH function increased as follows: < 25%, 29%, 37%, and 45.6%, and this increase in C1-INH function was associated with the reduced frequency of acute attacks. AML, acute myeloid leukemia; BMT, bone marrow transplantation; C1-INH, C1-inhibitor; HAE, hereditary angioedema